

Supplementary Table 7A. Objective response rate showing N (%) of overall responders and OR (95% CI) according to IHC 0-1 vs. 2+ biomarker status.

Biomarker	0-1 N (%)	2+ N (%)	N	OR (95% CI)
pAkt	11 (14.5)	0 (0.0)	77	NE
pS6	5 (12.2)	6 (17.1)	76	1.5 (0.4 – 5.6)
HIF-1 α	9 (14.8)	1 (10.0)	71	0.6 (0.0 – 4.1)
c-kit	10 (14.5)	0 (0.0)	74	NE
c-MET	6 (16.7)	4 (11.8)	70	0.7 (0.2 – 2.6)

Supplementary Table 7B. Objective response rate showing N (%) of overall responders OR (95% CI) for patients by treatment and IHC 0 vs. 1+ biomarker status.

Biomarker	Sunitinib			Everolimus		
	N	0-1 N (%)	2+ N (%)	N	0-1 N (%)	2+ N (%)
pAkt	34	7 (19.4)	0 (0.0)	41	4 (10.0)	0 (0.0)
pS6	36	2 (10.5)	5 (29.4)	40	3 (13.6)	1 (5.6)
HIF-1 α	33	6 (21.4)	1 (20.0)	38	3 (9.1)	0 (0.0)
c-kit	36	7 (20.6)	0 (0.0)	38	3 (8.6)	0 (0.0)
c-MET	34	4 (21.1)	3 (20.0)	36	2 (11.8)	1 (5.3)